Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Fatigue Reduction Diet for Lymphoma

In this study the investigators are proposing to measure the how well it works, sustainability, and mechanisms of 3 months of individualized counseling of the FRD delivered by registered dietitians, over 8 sessions by phone/video conferencing on fatigue, quality of life, and associated symptoms in persistently fatigued lymphoma cancer survivors compared to 3 months of individualized counseling of the attention control (matched for time and frequency of interactions with the FRD) the General Health Curriculum (GHC). The investigators will randomize and follow 68 lymphoma cancer survivors; accounting for a \~10% drop out rate to achieve a target of 60 patients that will complete the study.

Official registry: https://clinicaltrials.gov/study/NCT06047626 · University of Michigan Rogel Cancer Center · enrollment listed as 100

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Fatigue Reduction Diet, or General Health Curriculum. The registry lists allocation as randomized. In this study the investigators are proposing to measure the how well it works, sustainability, and mechanisms of 3 months of individualized counseling of the FRD delivered by registered dietitians, over 8 sessions by phone/video conferencing on fatigue, quality of life, and associated symptoms in persistently fatigued lymphoma cancer survivors compared to 3 months of individualized counseling of the attention control (matched for time and frequency of interactions with the FRD) the General Health Curriculum (GHC).

They plan to enroll about 100 people at Ann Arbor. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

Living Well With Lymphoma: Improving Diet Quality to Improve Energy, Sleep and Quality of Life

Interventions: Fatigue Reduction Diet, General Health Curriculum

Primary outcome (registry wording): Brief Fatigue Inventory

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Women and men aged 18 years and older
  • Diagnosis of lymphoma (Hodgkin and non-Hodgkin)
  • Have an average persistent fatigue defined as ≥ 4 on the Brief Fatigue Inventory
  • Fatigue must be attributed to lymphoma diagnosis
  • Fatigue onset must be between 12months before diagnosis and any time after diagnosis
  • Fatigue must not be attributed to other disease diagnoses
  • Fruit and vegetable intake ≤5.5 servings/day

Public study contact (from the registry)

Sara Snyder

734-998-7124

fammed-szickstudy@med.umich.edu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocy…

Background The development of new technologies now allow scientists to investigate the molecular basis and clinical manifestations of monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these methods in a natural history study can help identify processes involved in disease progression, and possibly lead to the discovery or validation of treatment targets.

NCT00923507 · Official ClinicalTrials.gov record · National Heart, Lung, and Blood Institute (NHLBI)

RecruitingNot a traditional drug phaseSioux Falls, South Dakota
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.

NCT01793168 · Official ClinicalTrials.gov record · Sanford Health

FAQ about this NCT record

Is NCT06047626 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06047626?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06047626?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary